CureVac in 'advanced' talks with EU to supply 225M coronavirus vaccine doses

CureVac and the EU have moved into “advanced discussions” in a potential deal to supply 225 million doses of the company’s mRNA-based COVID-19 vaccine candidate. The deal, which is contingent on the vaccine succeeding in testing, would also include an option to purchase another 180 million doses.